ANN ARBOR, MI, NOTA Laboratories, a development stage company focused on proprietary nitric oxide (NO) delivery systems to treat a wide variety of serious respiratory and inflammatory illnesses, has completed its second round of financing led by Pegasus Tech Ventures.

Founded in 2014, NOTA Laboratories is focused on developing NO delivery platform technologies that have broad applicability in advancing the treatment for many debilitating and potentially life-threatening conditions and diseases, including Sars CoV-2 (COVID-19), the seasonal flu, the common cold, systemic inflammatory response syndrome (SIRS), chronic rhinosinusitis (CRS), COPD, and catheter related bloodstream infection (CRBSI).